tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Immatics N.V. Reports Q3 2025 Financial Results and Progress
PremiumCompany AnnouncementsImmatics N.V. Reports Q3 2025 Financial Results and Progress
2M ago
Immatics price target raised to $23 from $19 at Mizuho
Premium
The Fly
Immatics price target raised to $23 from $19 at Mizuho
2M ago
Immatics price target raised to $19 from $16 at Guggenheim
Premium
The Fly
Immatics price target raised to $19 from $16 at Guggenheim
2M ago
Promising Efficacy and Safety of Immatics’ IMA402 and IMA401 Drive Buy Rating
PremiumRatingsPromising Efficacy and Safety of Immatics’ IMA402 and IMA401 Drive Buy Rating
2M ago
Immatics Reveals Promising Phase 1a Results for TCR Bispecifics
Premium
Company Announcements
Immatics Reveals Promising Phase 1a Results for TCR Bispecifics
2M ago
Immatics announces updated Phase 1a dose escalation data for IMA402, IMA401
Premium
The Fly
Immatics announces updated Phase 1a dose escalation data for IMA402, IMA401
2M ago
Immatics Reports Promising Anzu-cel Results in Uveal Melanoma
PremiumCompany AnnouncementsImmatics Reports Promising Anzu-cel Results in Uveal Melanoma
3M ago
Immatics highlights anti-tumor activity of anzu-cel PRAME cell therapy
Premium
The Fly
Immatics highlights anti-tumor activity of anzu-cel PRAME cell therapy
3M ago
Immatics Appoints New CFO to Drive PRAME Therapy Commercialization
Premium
Company Announcements
Immatics Appoints New CFO to Drive PRAME Therapy Commercialization
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100